Saturday, January 29, 2011

Breast Cancer Stem Cell Targets-Cancer Network

Translate Request has too much data
Parameter name: request
Translate Request has too much data
Parameter name: request
Breast Cancer Stem Cell Targets - Cancer Network #banner {text-align: left;padding-left: 25px;float: left;padding-top: 15px;height: 55px;}#banner .logo {display: block;background: transparent url(/image/layout_set_logo?img_id=46123&t=1296067224366) no-repeat;width: 375px;height: 55px;margin: 0px 0 0 0px;}#p_p_id_CMP_AD_DISPLAY_INSTANCE_tMcS_ {}#p_p_id_EXT_4_ {}#p_p_id_56_INSTANCE_rhC7_ {}#p_p_id_CMP_AD_DISPLAY_INSTANCE_0YkK_ {}#p_p_id_CMP_AD_DISPLAY_INSTANCE_KZvO_ {}#p_p_id_MostPopular_ .portlet {}#p_p_id_CMP_AD_DISPLAY_INSTANCE_4mer_ {}#p_p_id_SearchMedica_ .portlet {}#p_p_id_CMP_AD_DISPLAY_INSTANCE_ZNKo_ {}#p_p_id_CMP_AD_DISPLAY_INSTANCE_pqNx_ {}#p_p_id_EXT_6_INSTANCE_OrZR_ {margin-top: -15px;margin-right: 0px;margin-bottom: 0px;margin-left: 0px}#p_p_id_56_INSTANCE_qW2x_ {}window.fbAsyncInit = function() {FB.init({appId : 122621537768524,status : true, // check login statuscookie : true, // enable cookies to allow the server to access the sessionxfbml : true // parse XFBML});};(function() {var e = document.createElement('script');e.src = document.location.protocol + '//';e.async = true;document.getElementById('fb-root').appendChild(e);}());  Login EmailPasswordCancerNetworkMembers: Login | RegisterCancerNetworkSearchMedicaMedlineDrugs

Powered by SearchMedica

 PublicationsNewsConferencesPodcastsCMEClassifiedsSupplementsFor PatientsFor NursesCancer Management Handbook 

Home ? Breast Cancer.firefox .portlet-boundary_EXT_4_ #article-comments p sup {/*font-size:15px;line-height:1.7;text-align:left;*/}.ie #article-comments table {margin-bottom:12px;margin-top:-8px;}#article-comments div {font-size:12px;line-height:1.7;text-align:left;}.ie .article-comments-date {margin-bottom: 5px;}
ONCOLOGY.Vol. 25No. 1COMMENTARY Breast Cancer Stem Cell TargetsThe Federici et al Article Reviewed [READ ARTICLE]By Wendy A. Woodward, MD, PhD1 |January 22, 20111 Department of Radiation Oncology, M. D. Anderson Cancer Center, Houston, Texas

The publication of the landmark paper by Al-Hajj et al, which demonstrated that breast cancer cells capable of tumor outgrowth when transplanted into the cleared mammary fatpad of immunocompromised mice could be prospectively identified using cell surface markers,[1] galvanized the cancer stem cell debate among breast cancer researchers and launched an exponential increase in papers exploring “breast cancer stem cells.” In this issue of ONCOLOGY, Federici et al review this explosion of literature in a clear and concise article that, like all broad reviews of rapidly expanding, highly debated fields, is greatly constrained by the need for brevity.

The dramatic discourse that was launched by Al-Hajj’s work, which suggested that solid tumors such as breast cancer could be completely recapitulated by only a small fraction of the tumor cells, was initially dominated by the stem cell purists’ demand for clear and rigorous definitions of cancer stem cells. Ideally, in every report, each system, surrogate, tissue, or cell line studied was to be interrogated for the hallmarks of cancer stem cells: self-renewal, multipotency, and quiescence. Inevitably, however, the demonstration, in a small number of reports adhering to these standards, that markers and culture techniques can identify or enrich for self-renewing “cancer stem cells,”[2, 3] has led to surrogates, such as those described by Federici et al—eg, mammosphere formation or aldehyde dehydrogenase activity—being equated to cancer stem cells in the absence of functional studies to complement this work. In addition, properties well studied in normal hematopoietic stem cell biology and in hematologic cancer stem cell biology have been assumed to be relevant to solid tumor stem cells, in many cases in the absence of comparable solid tumor data. Thus, perhaps the greatest omissions in the breast cancer stem cell reviews to date, including those by this author (WAW) have been the failure to separate the rigorous work incorporating functional cancer stem cell assays from those relying primarily on marker studies, and the failure to fairly reflect the limitations and complexities of the current literature.

It is clear that the percentage of cancer stem cells identified in a tumor can be highly variable—a function of the technique used to transplant the cells[4]—and it is conceivable that the absence of appropriate microenvironmental signals from the host limits tumor initiation to only a few cells in this artificial condition.[5] While some studies in syngeneic mouse models in which the host microenvironment is intact have demonstrated that the capacity to re-initiate the tumor is indeed limited to a small population of prospectively identifiable cells,[6] it remains to be seen whether this is true across all syngeneic mammary tumor models—and even harder to prove, across any or all in situ human tumors. Concordance between findings in syngeneic mouse models and human tumor xenografts is reassuring, however. In a novel study with parallel findings in both systems, Atkinson et al have recently demonstrated the proof in principle that sub-lethal radiation alone can shrink the tumors but enrich for the resistant tumor-initiating cells in both p53 null mammary tumors and triple negative human xenografts. In contrast, the combination of hyperthermia and radiation simultaneously decreases both the tumor bulk and the tumor-initiating capacity.[7] Rigorous therapy-based studies in multiple models, such as this report by Atkinson et al, suggest that the potential caveats regarding anti–cancer stem cell therapies, including the possibility of dedifferentiation by differentiated cells to replace targeted cancer stem cells, may not be insurmountable obstacles.

Ultimately, proving the value of cancer stem cell studies will require clinical data demonstrating that targeting cancer stem cells improves breast cancer survival. If the biology of normal stem cells teaches us something about the biology of cancer that leads to more cures, it will not matter whether the cells are stem cells, progenitors, tumor-initiators, or self-renewing cells. For now, though, it remains unclear whether breast cancer stem cell targets represent the heart of the beast or just something at which to aim.

Financial Disclosure: The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

 Add your own comment

This commentary refers to the following articleBreast Cancer Stem Cells: A New Target for Therapy


1. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.

2. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-70.

3. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555-67.

4. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-8.

5. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324:1670-3.

6. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008;68:4674-82.

7. Atkinson RL, Zhang M, Diagaradjane P, et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med.2:55ra79.

CancerNetwork on Facebook


.date2 {color:#8C8C8C;font-family:Arial,Helvetica,sans-serif;font-size:12px;padding-left:0.4px;text-decoration:none;}Study Links Smoking to Breast Cancer
January 26, 2011.date2 {color:#8C8C8C;font-family:Arial,Helvetica,sans-serif;font-size:12px;padding-left:0.4px;text-decoration:none;}Cancer Age: Can We Reliably Estimate and Apply This Knowledge?
ONCOLOGY, January 24, 2011.date2 {color:#8C8C8C;font-family:Arial,Helvetica,sans-serif;font-size:12px;padding-left:0.4px;text-decoration:none;}Understanding the Kinetics of Cancer: Implications from Prevention to Prognostication
ONCOLOGY, January 24, 2011.date2 {color:#8C8C8C;font-family:Arial,Helvetica,sans-serif;font-size:12px;padding-left:0.4px;text-decoration:none;}How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers
ONCOLOGY, January 24, 2011.date2 {color:#8C8C8C;font-family:Arial,Helvetica,sans-serif;font-size:12px;padding-left:0.4px;text-decoration:none;}How Long Have I Had My Cancer, Doctor?
ONCOLOGY, January 24, 2011BreastCancer Topic Center


• Bladder Cancer
• Bone Metastases
• Breast Cancer
• Cancer and Genetics
• Carcinoid Tumors
• Colorectal Cancer
• End-of-Life Transition
• Gynecologic Cancers
• Head & Neck Cancer
• Integrative Oncology
• Kidney Cancer
• Leukemia/Lymphoma
• Lung Cancer

• Melanoma
• Multiple Myeloma
• Nausea & Vomiting
• Nurses
• Palliative Care
• Pancreatic Cancer
• Practice Management
• Practice & Policy
• Prostate Cancer
• Renal Cell Carcinoma
• Skin Cancer
• Survivorship
• Triple-Negative Breast
• Testicular Cancer
• All Topics


  MOST POPULAR function tabSwitch(active, number, tab_prefix, content_prefix) {for (var i=1; i Most PopularMost EmailedMost RecentRoche appeals FDA decision on AvastinUnderstanding and Treating Triple-Negative Breast CancerIpilimumab: A Promising Immunotherapy for MelanomaCurrent Concepts in Surgical Management of Neck Metastases from Head and Neck CancerCancer Management Chapter 1: Head and neck tumorsChemo plus radiation beats surgery in muscle invasive bladder cancerIpilimumab: A Promising Immunotherapy for MelanomaMyth Busting: Does Real-World Experience Lead to Better Drug Choices?Ipilimumab and melanoma: Rejoicing, disappointment, and threatManagement of Follicular Lymphoma in the Up-Front and Relapsed SettingsStudy Links Smoking to Breast CancerASCO Issues New End-of-Life Policy Statement and Patient GuideCancer Age: Can We Reliably Estimate and Apply This Knowledge?Understanding the Kinetics of Cancer: Implications from Prevention to PrognosticationHow Long Have I Had My Cancer, Doctor?Click here to subscribe to our newsletter

  SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Bone MetastasesEvidence on Bone MetastasesGuidelines on Bone MetastasesPatient Education on Bone MetastasesClinical Trials on Bone MetastasesPractical Articles on Bone MetastasesResearch and Reviews on Bone Metastases All "Bone Metastases" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | | Physicians Practice | Psychiatric Times | SearchMedica

? 1996 - 2011 UBM Medica LLC, aUnited Business Media company
Privacy Statement -Terms of Service - Advertising Information - Editorial Policy Statement

  ADDITIONAL ONLINE RESOURCES FROM UBM MEDICA Featured Resources > Psychiatry Careers > Practice Management Conference > Today's Practice - Practice Management Resource > RSV Information CancerNetwork > Cancer diagnosis, treatment, and prevention > Podcasts for Oncologists > Cancer Patient Resources > Oncology Areas of Confusion > Oncology News > Cancer Management Handbook > Breast Cancer Resource > ASH 2010 Conference Coverage > SABCS 2010 Coference Coverage Consultant Live > Diabetes Resources > Pediatric Asthma > Practical Clinical Advice > Medical Photoclinic > Diagnosing and Treating H1N1 flu (swine flu) > Primary Care Conference Reports > Community Acquired MRSA Diagnostic Imaging > Medical Imaging News and Features > Medical Imaging and Radiology White Papers> Radiology Conference Reports > Radiology Special Reports > Radiology Product Directory > RSNA 2010 Conference Coverage > Radiology Vendors Psychiatric Times > Psychiatric News and Special Reports > Psychiatric Clinical Scales > Psychiatric Times Blog > Psychiatry Career Opportunities > DSM-5 > Major Depressive Disorder Physicians Practice > Practice Management > EMR Software > Medical Practice Management Software > Medical Buyers Guide > Medical Coding > Practice Management Blog > EHR Resources > RVU > Practice Management White Papers SearchMedica > Professional Medical Search Engine > Medical Search Insights Blog > SearchMedica App for iPhone > Diabetes Research and Articles > Reflux Diseases Research and Articles Musculoskeletal Network > Muscle, Bone, Joint Medical Resources > Rheumatoid Arthritis Resource Center > Osteoarthritis Resource Center > Osteoporosis Resource Center The AIDS Reader > HIV News, Treatment, and Diagnosis for Medical Professionals > Women's Health, Obstetrics, Gynecology, Menopause, OBGYN > Gynecologic Oncology > Infertility > Menopause and Perimenopause > Hysterectomy and Alternatives > Urogynecology CME LLC > Continuing Medical Education > Psychiatry CME > Oncology CME > Practice Management CME > Primary Care CME > Psychiatric Congress > Performance Improvement CME > Treating the Whole Patient (TWP) — The Mind-Body Connection More Resources > Consumer Healthcare Information > Patient and Caregiver Resource > Search drug information, interactions, images & diagnosis > Drug index, news and CME from Asia > Infectious Diseases > Respiratory Disease

View the original article here

No comments:

Post a Comment